bacterium
clostridium
botulinum
caus
agent
botulisma
sever
intox
caus
botulinum
neurotoxin
bont
character
damag
nervou
system
effort
develop
novel
c
botulinum
immunotherapeut
camelid
singledomain
antibodi
sdab
vhh
nanobodi
could
use
due
uniqu
structur
characterist
studi
vhh
produc
use
phage
display
technolog
total
differ
monoclon
vhh
select
base
comlementaritydetermin
region
sequenc
differ
toxin
lethal
dose
ld
challeng
select
phage
clone
conduct
vivo
check
neutral
potenc
demonstr
modif
neutral
vhh
human
immunoglobulin
g
igg
fc
fragment
crystalliz
fragment
fusionbodi
vhhfc
significantli
increas
circul
time
blood
day
time
vhhfc
show
protect
activ
time
higher
monomer
form
challeng
ld
moreov
vhhfc
remain
protect
even
day
antibodi
administr
result
indic
vhhfc
could
use
effect
long
term
antitoxin
protect
botulinum
type
key
contribut
fusion
antibotulinum
vhh
fc
fragment
significantli
increas
protect
activ
vivo
serum
antibodi
circul
time
botulinum
neurotoxin
bont
strongest
organ
poison
human
anim
produc
anaerob
gramposit
sporeform
rodshap
bacterium
clostridium
botulinum
estim
human
lethal
dose
nanogram
per
kilogram
bodyweight
toxin
inhal
one
microgram
taken
oral
common
form
natur
botul
foodborn
wound
infant
foodborn
botul
occur
contamin
food
ingest
case
fatal
rate
develop
countri
oppos
wound
botul
occur
open
wound
expos
c
botulinum
spore
case
fatal
approxim
patient
even
aggress
treatment
infant
intestin
botul
occur
spore
ingest
spread
digest
tract
infant
lack
protect
flora
adult
case
fatal
rate
estim
le
ss
inhal
botul
occur
natur
may
occur
context
bioterrorist
attack
among
four
major
human
pathogen
bont
bonta
b
e
f
bonta
pose
seriou
challeng
medic
treatment
due
extrem
high
potenc
extraordinari
persist
human
patient
accord
world
health
organ
antitoxin
usual
base
equin
antitoxin
administ
soon
diagnosi
made
howev
side
effect
allerg
reaction
fever
serum
sick
anaphylact
shock
often
occur
past
atrisk
person
popul
vaccin
chemic
inactiv
pentaserotyp
bonta
toxoid
howev
use
discontinu
due
declin
potenc
affect
individu
botul
treatment
mainli
support
mechan
ventil
effect
lifesav
treatment
good
altern
antitoxin
serum
minim
side
effect
treatment
monoclon
antibodi
mab
bont
prduce
vitro
along
convent
antibodi
singledomain
antibodi
sdab
also
refer
vhh
variabl
domain
heavychain
stibodi
nanobodi
wide
use
sinc
discoveri
camelid
along
classic
immunoglobulin
igg
absenc
light
chain
igg
lack
constant
domain
heavi
chain
key
characterist
heavychain
antibodi
hcab
therefor
antigenbind
site
hcab
form
singl
domain
link
directli
via
hing
region
fc
fragment
crystalliz
domain
hcab
recogn
antigen
one
special
variabl
domain
refer
vhh
structur
vhh
domain
resembl
vh
igg
domain
complementaritydetermin
region
hcab
possess
extraordinari
capac
form
long
fingerlik
extens
extend
caviti
antigen
often
much
longer
convent
vh
domain
despit
small
size
kda
sdab
maintain
affin
antigenbind
specif
compar
fullsiz
mab
clear
advantag
includ
abil
recogn
hidden
antigen
site
inaccess
convent
antibodi
due
structur
stabil
wide
rang
temperatur
ph
high
solubl
well
econom
facil
express
product
larg
quantiti
microorgan
sever
studi
conduct
test
potenc
vhh
inhibitor
viral
infect
differ
toxin
produc
plant
microorgan
ricinu
communi
mycoplasma
homini
clostridium
tetani
clostridium
difficil
crotalu
durissu
terrificu
shiga
toxigen
escherichia
coli
stec
demonstr
antigenbind
region
vhh
produc
camelid
show
strong
antibont
activ
anim
model
due
uniqu
featur
high
efficaci
sdab
current
clinic
phase
trial
treatment
wide
rang
diseas
includ
cancer
inflamm
hematolog
respiratori
diseas
instanc
cablivi
nanobodybas
medicin
recent
approv
food
drug
administr
fda
acquir
thrombot
thrombocytopen
purpura
attp
treatment
howev
advantag
vhh
may
also
becom
impedi
small
size
enabl
good
penetr
tissu
rapid
distribut
short
halflif
blood
circul
limit
time
interact
hardtoreach
epitop
cross
endotheli
barrier
suffici
amount
nevertheless
due
rel
simpl
structur
vhh
optim
genet
engin
obtain
desir
properti
includ
extend
halfliv
one
approach
add
albuminbind
peptid
cterminu
vhh
antibotulinum
increas
serum
halflif
vhh
day
anoth
approach
gener
viru
vector
encod
chimer
protein
one
vhh
fuse
frame
cdna
encod
red
blood
cell
membran
protein
glycophorin
kell
vitro
studi
stem
cell
transplant
research
demonstr
halflif
vhh
could
extend
sever
week
retain
function
vhh
could
also
fuse
fragment
crystalliz
fc
region
igg
modif
term
fusionbodi
increas
total
protein
complex
size
well
vhhfc
interact
neonat
fcreceptor
fcrn
make
imposs
clear
renal
filtrat
system
furthermor
attach
fc
fragment
promot
effector
function
phagocytosi
cytotox
therebi
enhanc
neutral
pathogen
entri
replic
studi
focus
screen
specif
bonta
neutral
alpaca
vhh
vhh
antibodi
immun
librari
phage
display
use
bonta
bonta
treat
dithiothreitol
bontadtt
antigen
two
clone
high
neutral
potenc
lethal
dose
ld
obtain
phage
form
clone
produc
vhh
modifi
dimer
fuse
human
igg
fcfragment
vhhfc
fusionbodi
vhhfc
modif
greatli
increas
neutral
potenc
serum
halflif
alpaca
immun
perform
use
five
sequenti
inject
interv
day
first
second
immun
day
subsequ
immun
gener
immun
librari
singledomain
antibodi
figur
day
postimmun
blood
collect
bonta
specif
antibodi
titer
measur
enzymelink
immunosorb
assay
elisa
immun
serum
show
clear
respons
bonta
figur
immun
sera
show
background
level
antibodi
titer
final
titer
toxinspecif
antibodi
alpaca
serum
result
fivefold
immun
scheme
gener
panel
singledomain
antibodi
bonta
construct
alpaca
immun
vhh
librari
display
bacteriophag
surfac
clone
nucleotid
sequenc
code
vhh
repertoir
immun
alpaca
express
phagemid
vector
transform
recombin
phagemid
compet
e
coli
cell
librari
size
phagemid
obtain
phage
display
two
round
select
perform
acquir
phage
librari
purifi
bonta
use
antigen
first
round
two
independ
second
round
perform
separ
bonta
bontadtt
use
antigen
dtt
reduct
use
fragment
toxin
two
constitu
partsth
heavi
chain
hc
light
chain
lc
uniform
absorpt
chain
immunopl
surfac
evenli
distribut
epitop
chain
polyclon
phage
librari
titer
round
approxim
cfu
colonyform
unit
ml
figur
two
round
select
specif
librari
determin
elisa
figur
test
neutral
potenc
specif
polyclon
phage
librari
obtain
second
round
select
vivo
toxin
neutral
assay
perform
figur
balbc
femal
mice
divid
group
receiv
one
intraperiton
inject
ld
ld
bonta
h
incub
phage
librari
previous
obtain
phage
specif
tetanu
neurotoxin
tent
use
control
nonspecif
phage
mice
posit
control
group
surviv
mice
neg
control
group
tent
group
die
challeng
two
experiment
group
ld
ld
provid
full
partial
protect
thu
allow
select
monoclon
total
clone
show
elisa
readout
higher
figur
neglig
reactiv
bovin
serum
albumin
bsa
select
sequenc
total
clone
differ
amino
acid
sequenc
select
research
test
neutral
potenc
select
clone
vivo
monoclon
phage
neutral
assay
perform
mice
administ
correspond
phage
clone
figur
group
receiv
one
intraperiton
inject
ld
bonta
previous
mix
correspond
phage
clone
cfu
four
clone
fulli
protect
mice
ld
challeng
chosen
test
protect
ld
challeng
mous
group
receiv
clone
premix
bonta
partial
protect
two
group
receiv
clone
premix
bonta
show
protect
thu
clone
chosen
research
protect
note
clone
obtain
select
bontadtt
show
greater
divers
sequenc
demonstr
neutral
activ
unlik
clone
select
bonta
protect
clone
titrat
seri
cfu
introduc
intraperiton
mice
simultan
ld
toxin
neutral
potenc
clone
compar
lower
threshold
cfu
figur
final
clone
test
crossreact
protect
anoth
toxin
serotyp
bontb
group
mice
challeng
ld
toxin
administ
cfuml
phage
clone
fail
protect
mice
demonstr
two
protect
clone
specif
bonta
increas
protect
select
clone
increas
antibodi
circul
time
blood
andor
addit
function
two
modifi
construct
synthes
one
construct
dimer
form
clone
held
glycineserin
linker
express
plasmid
second
construct
monom
clone
link
human
igg
fc
fragment
figur
fcmodif
use
increas
antibodi
circul
time
blood
human
fcfragment
crossreact
murin
fcreceptor
capabl
bind
mous
fcrn
human
fc
chosen
construct
use
research
clinic
dimer
produc
purifi
bacteri
periplasm
fraction
verifi
sdspage
kda
vhh
fuse
fc
fragment
produc
chines
hamster
ovari
cho
cell
verifi
sdspage
kda
reduc
condit
figur
determin
polypeptid
chain
toxin
bound
specif
antibodi
denatur
dtt
hc
lc
sdspage
perform
denatur
condit
follow
western
blot
clone
test
antihuman
igg
fcspecif
peroxidas
antibodi
use
detect
reagent
figur
antibodi
associ
hc
kda
toxin
correspond
receptor
domain
immunoblot
bonta
bontadtt
reduc
condit
perform
control
figur
investig
affin
clone
via
surfac
plasmon
reson
spr
amin
coupl
use
immobil
bonta
bontadtt
sensor
chip
kinet
bind
onand
offrat
antibodi
toxin
determin
sensorgram
analysi
use
calcul
equilibrium
dissoci
constant
kd
tabl
tabl
kinet
paramet
antibodi
interact
toxin
obtain
spr
surfac
plasmon
reson
associ
onrat
k
dissoci
offrat
k
maximum
analyt
bind
capac
r
max
equilibrium
associ
constant
k
equilibrium
dissoci
constant
k
chi
chosen
vhh
variabl
domain
heavychain
antibodi
bind
botulinum
neurotoxin
bont
bontadtt
dithiothreitol
bontadtt
k
vivo
protect
analysi
modifi
form
vhh
differ
amount
monom
dimer
vhh
fuse
fc
fragment
premix
ld
bonta
inject
intraperiton
mice
figur
monom
partial
protect
even
highest
amount
protect
gradual
decreas
fail
dimer
show
better
result
averag
full
protect
partial
protect
lower
amount
fail
well
partial
protect
amount
fail
best
result
demonstr
vhh
fuse
fc
fragment
fail
fulli
protect
mice
protect
mice
amount
low
form
vhh
partial
protect
mice
high
amount
wherea
vhh
fuse
fc
fragment
could
protect
mice
even
lowest
amount
test
assess
circul
time
variou
antibodi
modif
blood
singl
inject
elisa
use
measur
concentr
mous
blood
taken
differ
time
point
inject
concentr
well
detect
h
postinject
initi
level
observ
h
howev
modif
construct
rel
long
serum
halflif
concentr
h
postinject
approxim
initi
level
moreov
two
week
inject
concentr
antibodi
approxim
initi
level
data
agreement
report
vhh
monomer
fusionbodi
format
figur
vhh
fuse
fc
fragment
demonstr
best
protect
mice
treat
prepar
aliv
two
week
end
experi
base
analysi
clone
circul
time
serum
presenc
antibodi
day
inject
decid
conduct
experi
surviv
mice
previous
receiv
singl
inject
vhh
fc
fragment
repeat
administr
lethal
toxin
dose
day
origin
administr
mice
challeng
bonta
ld
examin
protect
time
figur
mice
previous
receiv
vhhfc
still
fulli
protect
mice
previous
receiv
vhhfc
partial
protect
clone
clone
two
week
prepar
protect
also
test
prophylact
efficaci
possibl
treatment
toxin
administ
two
select
fcfuse
clone
one
hour
three
hour
toxin
challeng
ld
figur
clone
fulli
protect
mice
toxin
challeng
one
hour
three
hour
toxin
administr
clone
lack
protect
overal
obtain
numer
clone
two
round
biopan
select
clone
initi
analysi
base
chose
two
clone
best
premix
result
phage
form
vivo
produc
protein
form
modifi
structur
characterist
dimer
via
linker
fusion
human
igg
fc
fragment
enhanc
protect
activ
demonstr
modif
neutral
vhh
fc
fragment
fusionbodi
significantli
increas
circul
time
antibodi
blood
time
fc
fusion
significantli
increas
protect
activ
vhh
clone
time
compar
monomer
form
moreov
clone
increas
protect
activ
least
time
compar
monomer
form
protect
even
estim
molecular
ratio
ld
premix
bont
potent
lethal
known
toxin
therefor
develop
new
therapeut
agent
exposur
prevent
treatment
essenti
therapeut
approach
summar
previou
public
along
serum
therapi
specif
antibodi
promis
tool
neutral
bont
approach
gener
select
combin
modif
mab
bonta
describ
test
camelid
vhh
popular
tool
construct
recombin
antibodi
detect
neutral
rang
target
particular
shown
hconli
antibodi
vhh
deriv
hconli
antibodi
produc
camelid
demonstr
strong
antibont
activ
anim
model
main
differ
vhh
convent
antibodi
includ
specif
conserv
amino
acid
substitut
framework
region
make
contact
lc
classic
antibodi
well
longer
length
variabl
amino
acid
composit
fold
back
loop
specif
vhh
isol
vhh
librari
one
type
librariesimmun
librariescan
produc
base
peripher
blood
lymphocyt
isol
camelid
immun
antigen
interest
primeboost
strategi
studi
use
toxoid
consist
bonta
toxin
small
amount
hemagglutinin
ha
antigen
screen
vhh
bonta
bontadtt
use
phage
display
technolog
neutral
clone
work
select
bontadtt
note
neutral
clone
later
found
bonta
librari
well
howev
fewer
greater
number
clone
analyz
overal
approxim
clone
bontadtt
clone
bonta
librari
examin
approach
split
toxin
hc
lc
enrich
neutral
clone
librari
base
neutral
activ
premix
differ
toxin
ld
dose
two
clone
select
interestingli
clone
neutral
potenc
highest
elisa
signal
therefor
od
optic
densiti
elisa
signal
alway
mean
high
neutral
activ
vivo
protect
activ
vhh
next
step
produc
purifi
vhh
protein
form
test
neutral
potenc
vivo
howev
protect
weak
even
premix
dose
vhh
toxin
protect
effici
administr
lower
dose
prepar
nonprotect
lack
effect
therefor
two
modifi
increas
halflif
protect
efficaci
increas
vhh
size
oligomerizationth
coupl
two
vhh
via
specif
linkerincreas
protect
howev
even
bival
construct
rapidli
clear
anoth
approach
vhh
fusion
fc
region
igg
molecul
construct
fuse
fc
fragment
previous
made
extend
antibodi
halflif
neutral
middl
east
respiratori
syndrom
coronaviru
merscov
target
cxc
chemokin
receptor
type
prevent
human
immunodefici
viru
strain
entri
replic
vitro
increas
fc
effector
function
neutral
rotaviru
well
influenza
viru
ha
recent
studi
modifi
vhh
dimer
vhh
fuse
fc
target
uniqu
epitop
immunogen
compos
portion
central
deliveri
domain
entir
combin
repetit
oligopeptid
crop
domain
clostridium
difficil
type
b
show
modest
much
greater
toxin
inhibit
respect
note
combin
approach
effici
serum
clearanc
bonta
develop
sepulveda
et
al
use
singlechain
variabl
fragment
scfv
protein
bind
agent
precomplex
one
two
singl
antitag
mab
fc
domain
test
construct
vivo
protect
pharmacokinet
three
four
type
construct
given
simultan
mice
protect
high
ld
bonta
rapidli
clear
sera
protect
bonta
light
chain
observ
scfv
fuse
fc
fragment
scfvfc
obtain
macaqu
immun
librari
test
ex
vivo
furthermor
substanti
contribut
homolog
fc
fragment
potenc
three
individu
antibotulinum
mab
antibodi
prepar
demonstr
work
two
chosen
clone
dimer
via
linker
fusion
human
fc
fragment
stabil
molecul
slow
clearanc
modif
led
improv
protect
prepar
dimer
demonstr
protect
lower
dose
compar
vhh
protect
effici
clone
fail
protect
mice
like
vhh
clone
show
partial
protect
fail
therefor
effect
dose
ed
clone
clone
best
result
obtain
fusion
vhh
fc
fragment
consist
previou
research
clone
fulli
protect
mice
dose
low
protect
provid
half
clone
fail
protect
mice
demonstr
full
protect
lowest
test
dose
dose
protect
begin
decreas
reach
therefor
clone
fc
fragment
show
least
improv
protect
compar
convent
vhh
dimer
dose
clone
could
determin
clone
besid
pharmacokinet
analysi
variou
antibodi
form
show
clone
contain
igg
fc
fragment
detect
mous
serum
day
singl
inject
confirm
full
partial
anim
protect
challeng
toxin
day
administr
variou
dose
test
prophylaxi
possibl
treatment
toxin
administ
one
hour
three
hour
toxin
challeng
ld
show
clone
fulli
protect
mice
toxin
challeng
well
one
hour
fail
protect
mice
three
hour
toxin
administr
suggest
clone
could
use
prophylaxi
emerg
therapi
immedi
toxin
administr
correspond
result
obtain
previous
sepulveda
et
al
show
mice
receiv
scfv
precomplex
antitag
mab
fc
fragment
protect
two
hour
intox
four
hour
toxin
administr
lethal
delay
acquisit
antibodi
bonta
confirm
neutral
potenc
vivo
phage
form
premix
toxin
provid
new
method
screen
neutral
vhh
obtain
protein
form
effici
reduc
time
materi
cost
product
test
vhh
along
modif
oligom
fusion
fc
fragment
igg
increas
rang
option
bonta
target
neutral
improv
blood
circul
time
therapeut
potenti
alpaca
immun
blood
collect
perform
one
clinic
healthi
male
alpaca
vicugna
paco
russian
alpaca
farm
privat
land
locat
pokhodkino
moscow
region
russia
sampl
collect
involv
endang
protect
speci
specif
permiss
requir
locationsact
sixweekold
femal
balbc
mice
weigh
g
purchas
pushchino
breed
facil
pushchino
moscow
region
russia
accredit
associ
assess
accredit
laboratori
anim
care
aaalac
intern
maintain
central
anim
facil
gamaleya
research
center
epidemiolog
microbiolog
mice
kept
constant
temperatur
c
rel
humid
h
artifici
light
per
day
hous
individu
cage
per
cage
mice
fed
dri
food
water
ad
libitum
mice
observ
everi
two
hour
postinject
except
night
one
week
anim
characterist
symptom
botul
includ
muscl
paralysi
respiratori
difficulti
euthan
cervic
disloc
bonta
c
botulinum
strain
obtain
gamaleya
research
center
moscow
russia
collect
bonta
toxic
therefor
appropri
safeti
precaut
taken
experi
neurotoxin
handl
class
biosafeti
cabinet
antigen
toxoid
consist
bonta
toxin
small
amount
ha
formaldehyd
use
toxoid
prepar
treatment
carri
seven
day
c
mice
receiv
intraperiton
inject
determin
residu
toxic
show
absenc
use
alpaca
antigen
purifi
filter
final
concentr
immun
neurotoxin
inactiv
formaldehyd
ph
day
bonta
prepar
use
freund
adjuv
without
preadsorpt
alpaca
immun
perform
use
five
sequenti
inject
interv
day
first
second
immun
day
subsequ
immun
first
inject
time
ml
antigen
complet
freund
adjuv
sigma
st
loui
mo
usa
vv
ratio
administ
four
subsequ
immun
perform
ml
antigen
incomplet
freund
adjuv
sigma
st
loui
mo
usa
vv
ratio
small
blood
sampl
ml
collect
immun
well
third
fifth
immun
control
five
day
final
inject
ml
blood
sampl
collect
place
steril
vacuum
collect
tube
lithium
heparin
prevent
blood
clot
mrna
isol
pcr
amplif
librari
construct
perform
describ
elsewher
briefli
camelid
vhh
peripher
blood
blymphocyt
cellsml
immun
alpaca
clone
express
phagemid
vector
primer
set
use
pcr
amplif
antibodi
gene
append
sfii
neb
restrict
site
end
noti
neb
site
end
tabl
recombin
phagemid
introduc
freshli
prepar
compet
suppressor
e
coli
cell
lucigen
middleton
wi
usa
use
method
librari
individu
clone
biopan
isol
obtain
bacteria
vhh
librari
ad
yt
medium
sigma
st
loui
mo
usa
ampicillin
glucos
incub
c
cultur
shaker
rpm
helper
phage
patrick
chame
antibodi
therapeut
immunotarget
team
cancer
research
center
marseil
ad
bacteria
multipl
infect
moi
left
without
shake
c
min
cultur
centrifug
rpm
min
c
cell
pellet
resuspend
yt
medium
ampicillin
kanamycin
cultur
overnight
c
cultur
shaker
rpm
next
day
cultur
centrifug
supernat
purifi
concentr
polyethylen
glycol
peg
nacl
precipit
pellet
resuspend
phosphatebuff
salin
pb
glycerol
bontadtt
treat
mm
dtt
least
min
c
microtit
plate
well
coat
bonta
first
round
bonta
bontadtt
second
round
nahco
buffer
ph
c
overnight
rins
three
time
pb
tween
tpb
plate
block
block
buffer
tpb
nonfat
dri
milk
c
h
total
phage
ad
well
incub
c
h
unbound
phage
remov
wash
time
tpb
bound
phage
elut
trypsin
final
concentr
mgml
e
coli
cell
infect
elut
phage
incub
without
shake
c
min
cultur
mixtur
yt
agar
plate
ampicillin
glucos
c
overnight
cell
scrape
recombin
phage
obtain
packag
helper
phage
titer
determin
total
two
pan
round
perform
polyclon
elisa
immunopl
maxisorp
nunc
coat
ng
bonta
bontadtt
nahco
buffer
ph
c
overnight
plate
rins
three
time
tpb
block
block
buffer
c
h
total
phage
start
librari
first
second
round
ad
well
incub
c
h
unbound
phage
remov
wash
time
tpb
plate
well
detect
horseradish
peroxidas
hrp
conjug
antibodi
abcam
cambridg
uk
follow
addit
peroxidas
substrat
tetramethylbenzidin
tmb
biorad
hercul
ca
usa
reaction
stop
absorb
nm
read
iem
reader
mf
thermo
labsystem
waltham
usa
monoclon
elisa
perform
follow
protocol
particular
clone
bound
bonta
bontadtt
select
phage
plasmid
isol
sequenc
antibodi
gene
phagemid
sequenc
primer
set
use
pcr
accord
protocol
big
dye
termin
cycl
sequenc
kit
genet
analyz
appli
biosystem
waltham
usa
electrophoret
dna
separ
perform
cm
capillari
polym
select
vhh
express
plasmid
transform
e
coli
cell
neb
ipswich
usa
express
purif
overnight
cultur
obtain
c
cultur
shaker
rpm
next
day
cell
harvest
centrifug
lyse
bugbust
protein
extract
reagent
novagen
madison
wi
usa
vhh
purifi
lysat
talon
superflow
contain
co
agaros
ge
healthcar
bioscienc
ab
uppsala
sweden
elut
fraction
subject
dialysi
visk
dialysi
tube
mwco
serva
heidelberg
germani
vhh
separ
sdspage
biorad
hercul
ca
usa
denatur
condit
expect
molecular
weight
kda
antibodi
affin
determin
surfac
plasmon
reson
spr
use
biacor
instrument
ge
healthcar
bioscienc
ab
uppsala
sweden
bonta
bontadtt
immobil
surfac
sensor
chip
amount
mm
sodium
acet
buffer
ph
use
amin
coupl
kit
recommend
manufactur
ge
healthcar
bioscienc
ab
uppsala
sweden
vhh
dilut
captur
sensor
chip
submit
constant
flow
rate
hbsep
hepe
ph
nacl
mm
edta
vv
surfact
run
buffer
c
inject
time
min
dissoci
time
min
inject
chip
surfac
regener
mm
trishcl
ph
flow
rate
calcul
perform
use
biaevalu
softwar
ge
healthcar
bioscienc
ab
uppsala
sweden
referencesubtract
fit
select
vhh
held
glycineserin
linker
express
plasmid
protein
express
purif
perform
vhh
nucleotid
sequenc
vhh
gene
fuse
human
igg
fcfragment
synthes
clone
plasmid
pshuttlecmvfus
stratagen
la
jolla
ca
usa
cho
cell
cultur
thermofish
waltham
usa
transient
transfect
pfuse
plasmid
use
cho
gro
system
miru
bio
madison
wi
usa
accord
manufactur
protocol
plasmid
carri
green
fluoresc
protein
gene
amount
use
control
effici
transfect
assess
use
axio
imag
carl
zeiss
oberkochen
germani
determin
number
fluoresc
cell
compar
overal
amount
cell
cultur
shake
flask
rpm
co
humid
c
transfect
c
h
transfect
day
start
day
three
cellboost
hyclon
san
angeo
tx
usa
sigma
bioreactor
feed
sigma
st
loui
mo
usa
ad
day
day
cultiv
cultur
clarifi
centrifug
g
clear
filter
antibodi
purifi
use
protein
affin
chromatographi
akta
start
chromatographi
system
ge
healthcar
bioscienc
ab
uppsala
sweden
mabselect
sure
ml
column
ge
healthcar
bioscienc
ab
uppsala
sweden
accord
manufactur
protocol
determin
bonta
polypeptid
chain
bind
vhh
toxin
denatur
dtt
hc
lc
sdspage
perform
use
miniprotean
tgx
stainfre
precast
gel
biorad
hercul
ca
usa
denatur
condit
separ
band
transfer
onto
nitrocellulos
membran
use
transblot
turbo
system
biorad
hercul
ca
usa
membran
block
block
buffer
c
h
vhh
dilut
block
buffer
ad
membran
incub
c
h
rins
membran
three
time
tpb
antihistaghrpmous
antibodi
genscript
piscataway
nj
usa
dilut
block
buffer
ad
membran
incub
c
h
membran
rins
three
time
tpb
follow
addit
clariti
western
ecl
blot
substrat
biorad
hercul
ca
usa
detect
membran
visual
amersham
imag
ge
healthcar
buckinghamshir
uk
neurotoxin
multioligomer
complex
toxin
ntnha
nontox
nonhemagglutinin
kda
use
immun
toxin
prepar
purifi
follow
strain
cultiv
anaerob
condit
five
day
bacteri
cell
separ
centrifug
g
min
c
protein
cultur
filtrat
concentr
acid
precipit
ph
min
precipit
separ
centrifug
g
min
c
dissolv
mm
citratephosph
buffer
ph
gel
filtrat
ionexchang
chromatographi
akta
start
chromatographi
system
ge
healthcar
bioscienc
ab
uppsala
sweden
de
cellulos
pharmacia
uppsala
sweden
carri
toxin
kda
purifi
addit
de
cellulos
chromatographi
pharmacia
uppsala
sweden
borat
buffer
ph
elut
mm
nacl
nonsorb
materi
contain
specif
antigen
biolog
activ
use
bont
complex
ha
specif
antigen
activ
posit
reaction
monospecif
antibodi
bonta
ha
ntnha
gamaleya
laboratori
clostridiosi
commerci
prepar
scientif
centr
expert
evalu
medicin
product
russian
feder
phage
titer
cfuml
prepar
describ
mix
standard
salin
solut
vhh
protein
differ
amount
rang
prepar
describ
mix
standard
salin
solut
balbc
g
femal
mice
divid
group
four
includ
posit
neg
control
group
phage
vhh
protein
premix
appropri
toxin
ld
pg
bonta
incub
h
c
mice
receiv
one
intraperiton
inject
phage
protein
premix
variou
ld
toxin
observ
day
one
week
specif
patholog
pattern
observ
sick
mice
patholog
pattern
dystonia
abdomin
muscl
waistlin
increas
death
pg
neutral
monospecif
antibodi
bonta
posit
control
group
receiv
rabbit
antitoxin
igg
gamaleya
laboratori
clostridiosi
neg
control
group
receiv
standard
salin
solut
group
five
sixweekold
femal
balbc
mice
intraven
iv
inject
tail
vein
blood
collect
facial
vein
h
time
point
sera
separ
store
c
use
concentr
inject
antibodi
molecul
abovecollect
sampl
measur
elisa
elisa
bonta
coat
microtit
plate
nunc
overnight
c
ngwell
mm
bicarbon
buffer
wash
three
time
tpb
plate
block
dri
milk
pb
one
hour
c
dilut
sera
ad
well
follow
onehour
incub
mous
antihistag
antibodi
hrp
genscript
piscataway
nj
usa
use
detect
monom
dimer
antibodi
mous
sera
goat
antihuman
igg
